[1] Hartung HP, Mouthon L, Ahmed R, Jordan S, Laupland K, Jolles S. Clinical applications of intravenous immunoglobulins (IVIg)–beyond immunodeficiencies and neurology. Clin. Exp. Immunol. (2009)158(s1):23-33.
[2] Ruiz-Antorán B, et al. Use of non-specific intravenous human immunoglobulins in Spanish hospitals; need for a hospital protocol. Eur. J. Clin. Pharmacol. (2010)66(6):633-41.
[3] Pendergrast J, Sher G, Callum J. Changes in intravenous immunoglobulin prescribing patterns during a period of severe product shortages, 1995–2000. Vox sanguinis (2005)89(3):150-60.
[4] Jordan S, Toyoda M, Kahwaji J, Vo A. Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients. Am. J. Transplant. (2011)11(2):196-202.
[5] Jolles S, Sewell W, Misbah S. Clinical uses of intravenous immunoglobulin. Clin. Exp. Immunol. (2005)142(1):1-11.
[6] Mulhearn B, Bruce IN. Indications for IVIG in rheumatic diseases. Rheumatology (2014)54(3):383-91.
[7] Dodel R, et al. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet. Neurol. (2013)12(3):233-43.
[9] Holloway K, Green T, Organization WH. Drug and therapeutics committees: a practical guide. World Health Organization (2003).
[10] Angalakuditi M, Gomes J. Retrospective drug utilization review: impact of pharmacist interventions on physician prescribing.Clinicoecon Outcomes Res. (2011)3:105.
[11] Dashti-Khavidaki S, Khalili H, Farshadi F, Aghamohammadi A, Movahedi M, Hajibabaei M. Inpatient paediatric use of intravenous immunoglobulin at an academic medical centre. Singapore Med. J. (2008)49(2):147.
[12] Moore T, Bykov A, Savelli T, Zagorski A. Guidelines for implementing drug utilization review programs in hospitals. Management Sciences for Health, Arlington. World Health Organization (1997).
[13] Sohrevardi S, Shafiei A, Mirzania S. Intravenous Immunoglobulin: A Drug Utilization Review at Shahid Sadoughi Hospital in Yazd. J. Pharm. Care (2015)2(4):170-6.
[14] Alangari AA, Abutaleb MH, Albarraq AA, Al-Dhowailie AA. Intravenous immunoglobulin utilization in a tertiary care teaching hospital in Saudi Arabia. Saudi Med. J. (2008)29(7).
[15] Lin M, Kirkpatrick P, Riminton D. How intravenous immunoglobulin is used in clinical practice: audits of two Sydney teaching hospitals. Intern. Med. J. (2007)37(5):308-14.
[16] Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood (2011)117(16):4190-207.
[17] Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease.Circulation (2004)110(17):2747-71.
[18] IVIG guiding principle-The American Academy of Allergy, Asthma and immunology. Available online at : https://www.aaaai.org/Aaaai/media/MediaLibrary/PDF%20Documents/Practice%20Resources/IVIG-guiding-principles.pdf ?(accessed online in 2016)
[20] Network ORBC. Ontario Intravenous Immune Globulin (IVIG) Utilization Management Guidelines(2012)Version 2.
[21] Majer R, Hyde R. High‐dose intravenous immunoglobulin in the treatment of autoimmune haemolytic anaemia. Clin. Lab. Haematol. (1988)10(4):391-5.
[22] Wimperis J, Lunn M, Jones A, Herriot R, Wood P, O'Shaughnessy D, Qualie M. Clinical guidelines for immunoglobulin use: update. Department of Health Available at: https://www gov uk/government/uploads/system/ uploads/attachment_data/file/216671/ dh_131107 pdf. (2011) (accessed 01 June 2013)
[23] INIS Collaborative Group et al. Treatment of neonatal sepsis with intravenous ANDimmune globulin. N. Engl. J. Med. (2011)365(13):1201-11
[24] Ohlsson A, Lacy JB. Intravenous immunoglobulin for suspected or proven infection in neonates. Cochrane Database Syst. Rev. (2013)7.
[25] Geng J, Dong J, Li Y, Ni H, Jiang K, Shi LL, Wang G. Intravenous immunoglobulins for epilepsy. Cochrane Database Syst. Rev. (2011)(1).
[26] Sarti L, Falai T, Pinto F, Tendi E, Matà S. Intravenous immune globulin usage for neurological and neuromuscular disorders: an academic centre, 4 years experience. Neurol. Sci. (2009)30(3):213-8.
[27] Wu J, et al. Use of intravenous immunoglobulin in an Asian paediatric population over a 10‐year period. J. Paediatr Child Health (2013)49(8):629-34.
[28] Kerr J, et al. Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in Europe. Front Immunol. (2014)5.
[29] Robinson P, Anderson D, Brouwers M, Feasby TE, Hume H. Evidence-based guidelines on the use of intravenous immune globulin for hematologic and neurologic conditions. Transfus Med. Rev. (2007)21:S3-S8.
[30] Group NICRW. Criteria for the clinical use of intravenous immunoglobulin in Australia. National Blood Authority, Canberra, ACT, Australia (2012).
[31] Mikati MA, Kurdi R, El-Khoury Z, Rahi A, Raad W. Intravenous immunoglobulin therapy in intractable childhood epilepsy: open-label study and review of the literature. Epilepsy & Behavior (2010)17(1):90-4.
[32] Hanna K, Poulin-Costello M, Preston M, Maresky N. Intravenous immune globulin use in Canada. Can. J. Clin. Pharmacol (2002)10(1):11-6.
[33] Prasad A, Chaudhary S. Intravenous immunoglobulin in pediatrics: A review. Med. J. Armed Forces India (2014)70(3):277-80.